Polyethylene glycol conjugated interleukin-2: clinical and immunologic effects in patients with advanced renal cell carcinoma (Q72660738)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8262734%20AND%20SRC:MED&resulttype=core&format=json

28 October 2019

title

Polyethylene glycol conjugated interleukin-2: clinical and immunologic effects in patients with advanced renal cell carcinoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8262734%20AND%20SRC:MED&resulttype=core&format=json

28 October 2019

1 reference

R M Bukowski

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8262734%20AND%20SRC:MED&resulttype=core&format=json

28 October 2019

J Young

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8262734%20AND%20SRC:MED&resulttype=core&format=json

28 October 2019

G Goodman

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8262734%20AND%20SRC:MED&resulttype=core&format=json

28 October 2019

F Meyers

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8262734%20AND%20SRC:MED&resulttype=core&format=json

28 October 2019

B F Issell

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8262734%20AND%20SRC:MED&resulttype=core&format=json

28 October 2019

J S Sergi

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8262734%20AND%20SRC:MED&resulttype=core&format=json

28 October 2019

D McLain

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8262734%20AND%20SRC:MED&resulttype=core&format=json

28 October 2019

G Fyfe

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8262734%20AND%20SRC:MED&resulttype=core&format=json

28 October 2019

J Finke

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8262734%20AND%20SRC:MED&resulttype=core&format=json

28 October 2019

publication date

1 May 1993

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8262734%20AND%20SRC:MED&resulttype=core&format=json

Investigational New Drugs

28 October 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8262734%20AND%20SRC:MED&resulttype=core&format=json

28 October 2019

volume

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8262734%20AND%20SRC:MED&resulttype=core&format=json

28 October 2019

issue

2-3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8262734%20AND%20SRC:MED&resulttype=core&format=json

28 October 2019

page(s)

211-217

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8262734%20AND%20SRC:MED&resulttype=core&format=json

Relationship of effective molecular size to systemic clearance in rats of recombinant interleukin-2 chemically modified with water-soluble polymers.

28 October 2019

cites work

1 reference

12 December 2020

Biological Activity of Recombinant Human Interleukin-2 Produced inEscherichia coli

1 reference

12 December 2020

Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients

1 reference

12 December 2020

Clinical and immunological effects of recombinant interleukin 2 given by repetitive weekly cycles to patients with cancer.

1 reference

12 December 2020

Influence of dose and duration of infusion of interleukin-2 on toxicity and immunomodulation

1 reference

12 December 2020

Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer

1 reference

12 December 2020

Tumor-infiltrating lymphocytes in patients with renal-cell carcinoma

1 reference

12 December 2020

Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes

1 reference

12 December 2020

Chemical modification of recombinant interleukin 2 by polyethylene glycol increases its potency in the murine Meth A sarcoma model

1 reference

12 December 2020

A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone

1 reference

12 December 2020

Schedule dependency of the antitumor activity and toxicity of polyethylene glycol-modified interleukin 2 in murine tumor models.

1 reference

12 December 2020

Systematic preclinical study on the therapeutic properties of recombinant human interleukin 2 for the treatment of metastatic disease.

1 reference

12 December 2020

A phase I study including pharmacokinetics of polyethylene glycol conjugated interleukin-2.

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF00874158

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8262734%20AND%20SRC:MED&resulttype=core&format=json

28 October 2019

1 reference